RA
Ravi Aggarwal
About Ravi Aggarwal
Data last updated:
Ravi Aggarwal was a Ceo at Medall Healthcare Private Limited (2022–2025), Director at Clumax Diagnostic And Research Centre Private Limited (2022–2025) and Director at Medall Visakhapatnam Private Limited (2022–2025), and held 4 more directorships. The companies operate in Healthcare.
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Ceo | 27 Oct 2022 | 1994 | ₹159 Cr (FY 2023) | Active | |
| Director | 05 Dec 2022 | 2004 | ₹18.78 Cr (FY 2024) | Active | |
| Director | 05 Dec 2022 | 2018 | Active | ||
| Director | 05 Dec 2022 | 2015 | ₹18.08 Cr (FY 2024) | Active | |
| Director | 05 Dec 2022 | 2013 | ₹3.3 Lakh (FY 2024) | Active | |
| Director | 05 Dec 2022 | 2011 | ₹18.3 Lakh (FY 2024) | Active | |
| Director | 10 Oct 2019 | 1999 | ₹285 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Ravi Aggarwal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ravi Aggarwal
Ravi Aggarwal was first appointed on 10 Oct 2019 as Director at Agilus Pathlabs Private Limited. The most recent appointment on record is 05 Dec 2022 at Medall Scans And Labs Marthahalli Private Limited.
Ravi Aggarwal held 7 earlier board appointments: Medall Healthcare Private Limited (Ceo, 27 Oct 2022 to 31 Mar 2025); Clumax Diagnostic And Research Centre Private Limited (Director, 05 Dec 2022 to 31 Mar 2025); Medall Visakhapatnam Private Limited (Director, 05 Dec 2022 to 31 Mar 2025); Medall Scans And Labs Ranchi Private Limited (Director, 05 Dec 2022 to 31 Mar 2025); Medall Spark Diagnostics Nashik Private Limited (Director, 05 Dec 2022 to 31 Mar 2025); and 2 more.